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A stability-indicating high performance liquid chromatographic
(HPLC) method was developed and validated for the quantitation and
dissolution determination of topiramate in tablet dosage forms. An
isocratic separation was achieved using a phenyl column with a flow
rate of 1 mL/min using UV detection at 264 nm. Topiramate has low
UV absorbtivity and was subjected to derivatization with 9-fluorenyl-
methyl chloroformate (FMOC-Cl). The mobile phase for the separation
consisted of acetonitrile: 50 mM sodium dihydrogen phosphate
(NaH2PO4) containing 3 % v/v triethylamine (pH 2.8) in a 48:52 v/v
ratio. Topiramate was subjected to oxidation, hydrolysis, photolysis and
heat for the purposes of stress testing. Separation was achieved for the
parent compound and all the degradation products in an overall analytical
run time of approximately 15 min with the parent compound topiramate
eluting at approximately 9.2 min. The method was linear over the concen-
tration range of 1-100 µg/mL (r = 0.9996) with limits of quantitation
and detection of 1 and 0.3 µg/mL, respectively.
Key Words: Topiramate, Stability-indicating, UV-High performance
liquid chromatographic (UV-HPLC), Dissolution testing.
INTRODUCTION
Topiramate is chemically 2,3:4,5-bis-O-(1-methylethylidene)-β-d-fructopyranose
sulfamate (Fig. 1), a sugar derivative intended for use as an antiepileptic drug.
Pharmacologically the compound is characterized by a complex mechanism of action
and has the ability to affect most currently known mechanisms by which seizures
are induced1. Several HPLC2-10, gas chromatographic11-13 and fluorescence polari-
zation immunoassay14,15 methods for the quantitative determination of topiramate
in biological fluids are reported. A capillary electrophoresis method16 with indirect
UV detection and an ion chromatographic method17 have also been reported for
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monitoring inorganic sulfate and sulfamate degradation products in topiramate
dosage forms and active pharmaceutical ingredient (API). The published methods
are not directly applicable to the analysis of dissolution samples collected during
dissolution testing of topiramate tablets and require further investigation into method
development and subsequent validation.
Fig. 1. Structural formulae for topiramate (MW = 339.4)
Due to the lack of an intrinsic chromophore, topiramate is not readily monitored
by UV detection without appropriate pretreatment. The determination of topiramate
is feasible by derivatization with chromophoric agents2 and subsequent analysis by
HPLC. 9-Fluorenylmethyl chloroformate (FMOC-Cl) reacts with primary and seco-
ndary amines to form apolar UV-absorbing products which can be detected by UV
absorbance18. The aim of this study is to develop an HPLC-UV analytical procedure
for use in the routine analysis and dissolution testing of topiramate in tablets by
derivatization with FMOC-Cl. The US19 and British pharmacopoeias20 have yet to
include an official method for the quantitation of topiramate in dosage forms or for
use in dissolution testing. Furthermore the methods reported previously focused
primarily on the analysis of topiramate in biological fluids. Therefore the develop-
ment of an analytical method that is applicable for routine quality control of the
active pharmaceutical ingredients is beneficial. The method was validated in terms
of linearity, precision, accuracy, selectivity, limits of quantitation (LOQ) and detection
(LOD) and was applied to the quantitation and dissolution testing of topiramate in
tablets.
EXPERIMENTAL
Topiramate standard powder (100.5 %) was kindly supplied by Janssen-Cilag
(Berehem, Belgium) and was used without further purification. Topiramate tablets
containing 100 mg topiramate were purchased from a local pharmacy. Topamax®
(Janssen-Cilag, Berehem, Belgium) tablets were used as the reference formulation.
HPLC grade acetonitrile, triethylamine, NaH2PO4, boric acid, glycine, NaOH, HCl
and H2O2 were obtained from Merck (Darmstadt, Germany). 9-Fluorenylmethyl
chloroformate (FMOC-Cl) (≥ 99.0 %) was purchased from Fluka (Buchs, Switzerland).
All chemicals were at least of analytical grade and were used as received. Purified
HPLC grade water was prepared by reverse osmosis and filtration through a Milli-Q®
system (Millipore, Milford, MA, USA) and was used to prepare all solutions.
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HPLC instrumentation and conditions: The HPLC system consisted of a
Waters® 600 solvent delivery with a solvent degasser, a Waters® 717 plus autosampler,
a Waters® 486 tunable absorbance detector. Data was recorded, monitored and evaluated
using a Millenium® chromatographic data system that was coupled to the detector
via a SAT/IN Module (Waters Chromatography Division, Milford, MA, USA).
Chromatographic separation was achieved using a Perfectsil® target phenyl, 250
mm × 4.6 mm i.d., 5 µm column (Mainz, Germany) and a mobile phase consisting
of acetonitrile: 50 mM NaH2PO4 containing 3 % v/v triethylamine (pH 2.8) in a
ratio of 48: 52 v/v. Samples were injected at a constant flow rate of 1 mL/min and
the analytical wavelength was set at 264 nm. The column was maintained at 52 ºC
and 50 µL of samples were injected onto the column. The mobile phase was filtered
through 0.45 µm Chrom Tech Nylon-66 filter (Apple Valley, MN, USA) prior to use.
Preparation of stock and standard solutions: A stock solution of topiramate
(1 mg/mL) was prepared by accurately weighing approximately 20 mg of topiramate
into a 20 mL A-grade volumetric flask and making up to volume with HPLC grade
acetonitrile. The stock solution was protected from light using aluminium foil and
stored for 1 week at 4 °C. The stock solution was stable during this period. Aliquots
of the standard stock solution were transferred using A-grade bulb pipettes into 10 mL
volumetric flasks and the solutions were made up to volume with borate buffer to
produce final concentrations for the analytical standards of 1, 2, 5, 20, 50 and 100
µg/mL. The borate buffer was prepared by dissolving 6.25 g of boric acid and 7.50 g
of potassium chloride in 1000 mL of HPLC grade water and adjusting to a pH of
7.8 using a 1 M potassium hydroxide solution. A stock solution of glycine (10 mg/mL)
was prepared by dissolving glycine in HPLC grade water. The FMOC-Cl solution
(5 mg/mL) was prepared in acetonitrile and stored at 4 °C until required. Topiramate
standard solutions were then subjected to derivatization with FMOC-Cl as described
in the procedure described in the sample derivatization section of this manuscript.
Preparation of tablets for analysis: Twenty tablets were weighed, crushed
and mixed in a mortar and pestle. A portion of the powder equivalent to the weight
of one tablet was accurately weighed into each of six 50 mL A-grade volumetric
flasks and 25 mL of acetonitrile was added to each flask. The volumetric flasks
were sonicated for 15 min to effect complete dissolution of the topiramate and the
solutions were then made up to volume with purified HPLC grade water. Suitable
aliquots of solution were filtered through a 0.45 µm nylon filter (Chrom Tech, Apple
Valley, MN, USA) and 0.5 mL of the filtered solution was quantitatively transferred
to a 20 mL volumetric flask and made up to volume with borate buffer, prepared as
previously described, to yield a concentration of topiramate in the linear range of
the analytical method. The solution was then subjected to derivatization with FMOC-Cl
as described in the procedure described in the sample derivatization section of this
manuscript.
Forced degradation studies of active pharmaceutical ingredient (API) and
topiramate tablets: In order to determine whether the analytical method and assay
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were stability-indicating, topiramate tablets and topiramate API powder were stressed
under various conditions to conduct forced degradation studies. Regulatory guidance
provided in ICH21,22 require the development and validation of stability-indicating
procedures for the analysis of drugs and drug products. Unfortunately these guidance
documents do not indicate the detailed conditions required to conduct stress testing
studies. The experimental conditions required to conduct such stress tests are described
in a general manner in the documents and the exact conditions to be applied are not
explicitly stated. Furthermore the extent to which degradation should continue is
also not described. Some guidelines suggest that the experimental conditions required
for stress testing are dependent on the nature of the drug substance and the drug
product being tested. Typically the necessary stress conditions are determined on
the basis of the experience of the analyst conducting the studies or by trial and
error. The conditions used to effect degradation including the concentration of stress
agent used and the time of stress application was found to be effective and degradation
of not less than 10 % but without complete destruction of the topiramate was
achieved.
Oxidation, acid degradation, alkali degradation and neutral degradation
studies: Solutions for oxidation, acid degradation, alkali degradation and neutral
degradation studies were prepared in acetonitrile and 3 % H2O2 (50:50, v/v), aceto-
nitrile and 0.1 M HCl (50:50, v/v), acetonitrile and 0.1 M NaOH (50:50, v/v) and
acetonitrile and water (50:50,  /v), respectively. The resultant solutions were heated
for 1 h in a water bath at 70 °C in order to accelerate the degradation of the compound.
The solutions were diluted with borate buffer to yield starting concentrations of
topiramate of 100 µg/mL and were then subjected to derivatization with FMOC-Cl
using the conditions described in the sample derivatization section of this manuscript.
Temperature studies: In order to conduct temperature stress studies, 20 tablets
and API powder were exposed to dry heat (90 °C) in an oven for 3 days. The tablets
and API powder were removed from the oven and the tablets were weighed, crushed
and mixed in a mortar and pestle. An aliquot of powder equivalent to the weight of
one tablet and API powder were then prepared for analysis using the same conditions
and procedures described in the preparation of tablets for analysis.
Photostability studies: Topiramate API, tablet powder and solutions of
topiramate were prepared and exposed to light to determine the effects of light
irradiation on the stability of topiramate in solution and in the solid state. Approxi-
mately 50 mg of topiramate API powder was spread on a glass dish in a layer that
was less than 2 mm thick. A 1 mg/mL solution of topiramate powder was prepared
in acetonitrile and water (50:50, v/v). Tablets were prepared for analysis in a similar
manner to that previously described. All samples for photostability testing were
placed in a Suntest CPS/CPS+ light cabinet (Atlas Material Testing Technology,
Linsengericht, Germany) and exposed to light for 40 h resulting in an overall illumi-
nation of ≥ 210 w h/m2 at 25 °C with UV radiation of between 320-400 nm. Control
samples that had been protected with aluminium foil were also placed in the light
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cabinet and exposed at the same time as the test samples. Following exposure for
the desired period, samples were removed from the light cabinet and prepared for
analysis as described in the procedure in the sample derivatization.
Dissolution test conditions: Dissolution testing was performed using an
Erweka® (Heusenstamm, Germany) Model DT-700 USP Apparatus II (paddle).
Dissolution testing was undertaken by dropping a tablet (n = 12) into a dissolution
vessel containing a 900 mL dissolution medium (borate buffer, pH 7.8). The temp-
erature of the dissolution fluid was maintained at 37 ± 1 °C and the paddle was
rotated at a speed of 50 rpm for 50 min. Five milliliters of the receptor medium
were removed at 5, 10, 20, 30 and 45 min following the commencement of the
dissolution test. Five milliliters of the fresh dissolution medium was replaced into
each vessel after removal of the test sample. The samples were filtered through
Whatman No. 1 filter paper and analyzed using the proposed method as described
in the procedure for sample derivatization.
Procedure of sample derivatization: In order to derivatize the compound of
interest 50 µL FMOC-Cl solution was added to 100 µL of each sample and the
solutions were mixed for 20 s and then incubated at 50 °C for 15 min in a water
bath. In order to terminate the reaction, 10 µL of glycine solution was added to the
solution and mixture was vortexed for 10 s. The solution was allowed to stand for 1 min
prior to injection, of a 50 µL aliquot of the resultant solution, onto the chromatographic
system.
RESULTS AND DISCUSSION
Derivatization, HPLC method development and optimization: A derivatization
procedure in which FMOC-Cl was selected as the derivatizing agent was adapted2
for the analysis of topiramate in raw material and dosage forms. The optimum
conditions for the derivatization procedure included the use of a borate buffer and
a reaction temperature of 50 ºC with a reaction time of 15 min. It is important to
note that neither the ionic strength of the reacting medium nor the buffer concen-
tration affect the derivatization reaction18. The composition, pH and the flow rate of
the mobile phase in addition to the column temperature were altered in a systematic
manner in order to optimize the separation conditions using unstressed and stressed
test samples. Several preliminary investigatory chromatographic runs were evaluated
and optimal chromatographic separation was achieved using a Perfectsil® target
phenyl, 250 mm × 4.6 mm i.d., 5 µm column maintained at 52 ºC temperature with
a mobile phase mixture of acetonitrile: 50 mM NaH2PO4 containing 3 % v/v triethyl-
amine (pH 2.8) in a ratio of 48:52 v/v at a flow rate of 1 mL/min. The eluant was
monitored using UV detection at a wavelength of 264 nm. The peak shape of
topiramate was symmetrical under the experimental conditions described.
Validation: The method was validated with respect to linearity, limit of
quantitation (LOQ), limit of detection (LOD), precision, accuracy, selectivity and
recovery23-28.
3860  Mohammadi et al. Asian J. Chem.
Linearity: The linearity of the method was evaluated by least squares linear
regression analysis of three calibration curves constructed for topiramate over the
concentration range of 1-100 µg/mL. The peak area of topiramate was plotted versus
concentration and linear regression analysis performed on the resultant curve. The
resultant curves were found to be linear with correlation coefficients of R = 0.9999,
R = 0.9995 and R = 0.9996 for the three curves and with % RSD values ranging
from 0.22-3.25 % across the concentration range studied. A typical regression equation
for a calibration curve was found to be y = 0.495X + 4.85.
LOQ and LOD: The LOQ and LOD of the analytical method were determined
based on signal to noise (S/N) criteria. The respective values were found to be 1 µg/mL
(S/N = 10) and 0.3 (S/N = 3) for the LOQ and LOD, respectively.
Precision: Repeatability and reproducibility were evaluated to determine the
precision of the analytical method. Repeatability was investigated by injecting 10
replicate samples of each of the 1, 10 and 100 µg/mL standards where the mean
concentrations were found to be 1.02, 9.85 and 100.75 µg/mL with associated %
RSD, values of 1.85, 2.20 and 0.35 %, respectively. Inter-day precision was assessed
by injecting the same three concentrations over three consecutive days, resulting in
mean concentrations of topiramate of 1.03, 10.13 and 101.25 µg/mL and associated
% RSD values of 3.23, 2.95 and 1.7 %, respectively.
The ruggedness of the analytical method was assessed by comparison of the
intra- and inter-day assay results for topiramate following analyses undertaken by
two independent analysts. The % RSD values for intra - and inter- day determinations
of topiramate performed in the same laboratory by the two analysts did not exceed
3.5 %, thus indicating the ruggedness of the method. The mean retention time of
topiramate was 9.2 min with a % RSD of 0.12 %.
Accuracy: The accuracy of the assay procedure was determined by interpolation
of replicate (n = 6) peak areas of three accuracy standards (1, 10 and 100 µg/mL)
from a calibration curve prepared as previously described. In each case, the per
cent relevant error and accuracy was calculated. The resultant concentrations were
1.032 ± 0.030 mg/mL (mean ± SD), 10.152 ± 0.22 and 99.60 ± 0.35 mg/mL with
per cent relevant errors of 3.25, 1.55 and 0.43 %, respectively.
Selectivity: The results of stress testing studies indicate a high degree of selec-
tivity of this method for topiramate. The degradation of topiramate was found to be
similar for both the tablets and API powder. Typical chromatograms obtained follo-
wing the assay of pure bulk sample and stressed samples are shown in Fig. 2.
Recovery: A known amount of topiramate standard powder was added to
samples of tablet powder and the powders were then mixed, extracted and subse-
quently diluted to yield a starting concentration of 75 µg/mL and the solution was
analyzed as previously described. The recovery determination was repeated (n = 9)
over 3 consecutive days to obtain intermediate precision data. The observed concen-
tration of topiramate was found to be 74.95 ± 1.25 µg/mL (mean ± SD) and the
resultant % RSD value for these studies was found to be 1.67 % with a corresponding
percentage recovery of 99.93 %.
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 Fig. 2. Typical HPLC chromatograms of: (A) standard solution of active pharmaceutical
ingredient (API) showing topiramate (1); (B) neutral-hydrolysis degraded API (1 h
in a water bath at 70 °C); (C) untreated API in light cabinet(control); (D) acid
hydrolysis-degraded API; (E) dry heat-degraded API; (F) neutral-hydrolysis
degraded API (90 °C in an oven for 3 days); (G) photodegraded API; (H) oxidative
degraded API; (I) base hydrolysis-degraded API
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Stability studies: In the solid state and under normal storage conditions
topiramate is stable. However it degrades at elevated temperatures and humidity to
produce degradation and insoluble polymeric products in addition to the inorganic
anions sulfate and sulfamate16,17. In these studies the drug was subjected to oxidative,
hydrolytic, photolytic and heating conditions to apply stress to the molecule. All
stressed samples in both the solid and solution state remained colourless following
exposure to the different conditions. Topiramate was found to be unstable under
dry heat conditions and more than 95 % of the drug decomposed after exposure to
dry heat (90 °C) for 3 days. In spite of alkaline conditions, the drug was found to be
more stable in acidic conditions and the concentration decreased by 55 % on heating
for 1 h in a water bath at 70 °C. The drug was found to be more stable in light and
under oxidative stress conditions. The stability of the stock solution was determined
by quantitation of topiramate in the stock solution and then comparing the response
to that obtained from a freshly prepared standard solution. No significant change
(< 2 %) was observed in the stock solution response, relative to a freshly prepared
standard solution.
Application of the analytical method: The dissolution profiles generated follo-
wing dissolution testing under described conditions are shown in Fig. 3. It is clearly
evident that more than 90 % of the drug is released after 20 min. The percentage of
drug dissolved over time and the associated % RSD values are summarized in
Table-1. The difference (f1) and similarity factors (f2) were found to be 2.48 and
77.94, respectively, clearly indicating the curves are similar28.
 
Fig. 3. Dissolution profiles of topiramate (multisource) and Topamax® (reference) tablets
The proposed method was also applied to the determination of topiramate in a
multisource (generic) dosage form of topiramate and Topamax® tablets. A typical
chromatogram obtained following the assay of Topamax® tablets is depicted in Fig. 4.
The result of these analyses yielded 99.01 % (% RSD = 1.350 %) and 100.25 %
(% RSD = 1.40 %) of label claim for the generic product and Topamax® tablets,
respectively. The results of the assay and dissolution test indicate that the method is
selective for the analysis of topiramate without interference from the excipients
that are used in the production of these tablets.
120
100
80
60
40
20
0
D
ru
g 
di
ss
ol
ve
d 
(%
)
Topamax Topiramate
0 10 20 30 40 50
Time (min)
Vol. 22, No. 5 (2010) HPLC Analysis of Topiramate  3863
TABLE-1 
PERCENTAGE OF TOPIRAMATE DISSOLVED IN THE DISSOLUTION TEST (n = 12), 
USING BORATE BUFFER pH 7.8 MEDIUM AT 37 ± 1 ºC AND SPEED OF 50 rpm 
Drug dissolved (%), RSD (%) Time (min) 
Topiramate Topamax® 
5 
10 
20 
30 
45 
70.50, 2.54 
87.08, 1.10 
94.30, 0.65 
98.50, 0.25 
100, 0.30 
67.51, 3.15 
83.20, 1.45 
91.50, 0.53 
99.00, 0.17 
101, 0.43 
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Fig. 4. Resultant HPLC chromatograms obtained following the analysis of topiramate
tablets (A), topiramate standard   solution (100 µg/mL) (B) and Topamax® tablets
(C) showing topiramate (1)
Conclusion
An accurate, precise, selective stability-indicating HPLC analytical method
has been developed and validated for the determination of topiramate in API raw
material, tablet dosage forms and samples collected during dissolution testing. A
dissolution test procedure for application to topiramate tablets was developed using
900 mL of borate buffer (pH 7.8) and USP Apparatus II (paddle). The results of
stress testing undertaken according to the International Conference on Harmonization
(ICH) guidelines reveal that the method is selective and stability-indicating. The
simplicity of this HPLC-UV method allows for application in laboratories that lack
sophisticated analytical instruments such as LC-MS6-10 and that require compli-
cated and costly methods to successfully analyze test samples.
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